Innovation
In the 2022/2023 business year, we spent EUR 48 million on research and development
The Semmelweis University and Egis Pharmaceuticals PLC have agreed on an even closer cooperation than before. Our common goal is to further raise the standards of pharmaceutical R+D as well as pharmacist and doctor training by making use of the synergies in each other’s activities. As a result of the agreement, new health industrial innovations can be launched and the Semmelweis University can be extended with more practical educational and training elements that also meet the needs of the Hungarian pharmaceutical industry. More

New Unit Inaugurated at Egis’s Körmend Plant

Egis and our consortia partners have won 2,332 billion HUF direct grant in the framework of the innovation tender GINOP-2.2.1-15-2016-00023 for the realisation of the above-mentioned project.

More

Gran Prize - Egis Innovation for Sustainability

Egis has developed a new procedure for the dehalogenation of technological wastewaters. In 2018, the Swedish Chamber of Commerce in Hungary recognized the innovation with the Gran Prize Interdisciplinary Innovative award.

More

Environment Protection - Electric Cars in the Egis Fleet

It is important for us to protect the future of our planet, therefore we try to reduce our ecological footprint. Egis uses more and more electric cars in its fleet in order to minimize the harmful substance output.

More

Active Agent Production Renewed

By renewing our active agent base, we wish to simultaneously raise the rate of our active agents produced internally in a reliable quality and at a competitive price as well as to increase our exports.

More
WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox